Single-tablet, once-daily treatment regimens for HIV

• Published in: The Lancet infectious diseases Vol. 14; no. 4; pp. 265 - 267
• Main Authors: Sawyer, Joshua R, Ma, Qing, Hsiao, Chiu-Bin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.04.2014; Elsevier Limited
• Subjects: Adenine - administration & dosage; Adenine - adverse effects; Adenine - analogs & derivatives; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Antiretroviral drugs; Benzoxazines - administration & dosage; Benzoxazines - adverse effects; Carbamates - administration & dosage; Carbamates - adverse effects; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Drug Combinations; Drug dosages; Drug therapy; Emtricitabine; FDA approval; HIV; HIV Infections - drug therapy; HIV Integrase Inhibitors - administration & dosage; HIV Integrase Inhibitors - adverse effects; HIV Reverse Transcriptase - antagonists & inhibitors; Human immunodeficiency virus; Humans; Infectious Disease; Infectious diseases; Nitriles - administration & dosage; Nitriles - adverse effects; Organophosphonates - administration & dosage; Organophosphonates - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Quinolones - administration & dosage; Quinolones - adverse effects; Reverse Transcriptase Inhibitors - administration & dosage; Reverse Transcriptase Inhibitors - adverse effects; Rilpivirine; Tenofovir; Thiazoles - administration & dosage; Thiazoles - adverse effects

The combination of rilpivirine, tenofovir, and emtricitabine should not be used in patients with a high viral load (more than 100 000 copies per mL) because of an increased incidence of virological failure.3 Potential drug interactions between rilpivirine and gastric-acid reducers might also reduce...